This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Pharmacogenomics for Psychiatry: Focusing on Drug Metabolizing Enzymes and Transporters, with Validated Methodology for CYP2D6 and CYP2C19 Including for a Novel Sub-Haplotype
DownloadSpring 2022
Pharmacogenomics (PGx) is interested in the impact individual genetic makeup has on a patient’s response to pharmacological agents. In clinical practice, PGx has the potential of reducing adverse drug reactions (ADRs), which cost Canada $65 million dollars in the year 2018, as well as enhancing...
-
Fall 2022
Background: Pharmacogenomics (PGx) has potential to improve healthcare through personalized drug selection and dosing using genetic predictors of pharmacokinetics and/or pharmacodynamics (PK/PD). Research is uncovering PGx’s impact on morbidity and mortality from medication adverse effects and/or...